1
|
Jain V, Gupta H, Mehta N, Joshi D, Kataria H. Retrospective Comparative Analysis of Clinical and Functional Outcome After Arthroscopic Bankart Repair using All-Suture Anchor and Metal Anchor. Malays Orthop J 2024; 18:11-18. [PMID: 38638665 PMCID: PMC11023345 DOI: 10.5704/moj.2403.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2021] [Accepted: 05/19/2023] [Indexed: 04/20/2024] Open
Abstract
Introduction Both knotted all suture anchors and metal anchors are used for arthroscopic Bankart repair. We retrospectively evaluated and compared clinical and functional outcomes after arthroscopic Bankart repair using the knotted all-suture anchors and knotted metal anchors. Materials and methods In a retrospective cohort analysis, patients who underwent arthroscopic Bankart repair without any concomitant additional lesion repair using either all-suture anchors or metal anchors, between January 2015 and May 2018 were identified. Their pre- and post-operative functional and clinical outcomes were compared using Rowe and WOSI scores. The recurrence rate in the two groups was also compared. Results A total of 41 patients in all suture anchors group and 47 in the metal anchors group were identified as per inclusion and exclusion criteria. The demographic profile of both groups was comparable. There was no significant difference in clinical and functional outcome between the two suture anchor groups as per Rowe (pre-operative 40.13+6.51 vs 38.09+6.24 and post-operative 2 years 93.28+7.09 vs 92.55+9.2) and WOSI (pre-operative 943.05+216.64 vs 977.55+165.46 and post-operative 2 years 278.21+227.56 vs 270.94+186.25) scores. There was a significant improvement in both the groups between preoperative and post-operative ROWE and WOSI scores at 6 months and 2 years follow-up as compared to pre-operative scores (p<0.001). Re-dislocation rates were also comparable (4.8% vs 6.3%). Conclusion All-suture anchors showed comparable clinical and functional results as the metal anchors for arthroscopic Bankart repair at two-year follow-up.
Collapse
Affiliation(s)
- V Jain
- Sports Injury Centre, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India
| | - H Gupta
- Sports Injury Centre, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India
| | - N Mehta
- Sports Injury Centre, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India
| | - D Joshi
- Sports Injury Centre, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India
| | - H Kataria
- Sports Injury Centre, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, India
| |
Collapse
|
2
|
Bartsch YC, Cizmeci D, Yuan D, Mehta N, Tolboom J, De Paepe E, van Heesbeen R, Sadoff J, Comeaux CA, Heijnen E, Callendret B, Alter G, Bastian AR. Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine. J Virol 2023; 97:e0077123. [PMID: 37902399 PMCID: PMC10688327 DOI: 10.1128/jvi.00771-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 09/28/2023] [Indexed: 10/31/2023] Open
Abstract
IMPORTANCE Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine.
Collapse
Affiliation(s)
- Yannic C. Bartsch
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA
| | - Deniz Cizmeci
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
| | - Dansu Yuan
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA
| | - Nickita Mehta
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA
| | - Jeroen Tolboom
- Janssen Vaccines & Prevention B.V., Leiden, South Holland, the Netherlands
| | | | - Roy van Heesbeen
- Janssen Vaccines & Prevention B.V., Leiden, South Holland, the Netherlands
| | - Jerald Sadoff
- Janssen Vaccines & Prevention B.V., Leiden, South Holland, the Netherlands
| | - Christy A. Comeaux
- Janssen Vaccines & Prevention B.V., Leiden, South Holland, the Netherlands
| | - Esther Heijnen
- Janssen Vaccines & Prevention B.V., Leiden, South Holland, the Netherlands
| | - Benoit Callendret
- Janssen Vaccines & Prevention B.V., Leiden, South Holland, the Netherlands
| | - Galit Alter
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA
| | | |
Collapse
|
3
|
Yadav SK, Kumar A, Mehta N. Synthesis and characterization of nanostructured graphene-doped selenium. RSC Adv 2023; 13:13564-13574. [PMID: 37152579 PMCID: PMC10155193 DOI: 10.1039/d3ra01199b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Accepted: 04/18/2023] [Indexed: 05/09/2023] Open
Abstract
In this work, we explore various properties of elemental selenium glass (g-Se) by doping with graphene through the facile melt-quench technique. The structural information of the synthesized sample was found by X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), scanning electron microscopy (SEM), and Raman spectroscopy. The analyses confirm that the graphene-doped g-Se behaves like a glass-ceramic material. Electrical and dielectric measurements were performed to discover the consequences of graphene incorporation on the nano-structure of g-Se. The electrical measurements of the dielectric parameters (i.e., dielectric constant ε' and loss ε'') and conductivity (σ ac) reveal that graphene incorporation causes a rise in the dielectric constant but simultaneously increases dielectric loss. The enhancement in ε' and ε'' values is thought to be a consequence of the interface effect between graphene and the host selenium glass. Calorimetric experiments were performed in a standard differential scanning calorimetry (DSC) unit on the glassy nanocomposite in non-isothermal mode. By measuring the kinetic temperatures at four heating rates, the kinetics of the crystallization/glass transition were studied. The results were examined to understand the role of graphene doping on the well-known phase transitions (i.e., glass transition and crystallization) of g-Se.
Collapse
Affiliation(s)
| | - Amit Kumar
- Department of Physics, Banaras Hindu University Varanasi 221005 India
- Sunbeam College for Women Bhagwanpur Varanasi 221005 India
| | - N Mehta
- Department of Physics, Banaras Hindu University Varanasi 221005 India
| |
Collapse
|
4
|
Saraswat V, Pal SK, Mehta N, Kumar A, Imran MMA. Thermal analysis of novel third-generation phase-change materials with zinc as a chemical modifier. RSC Adv 2023; 13:3602-3611. [PMID: 36756576 PMCID: PMC9890671 DOI: 10.1039/d2ra07041c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Accepted: 01/07/2023] [Indexed: 01/27/2023] Open
Abstract
The thermal analysis in the present work is done to analyze the glass/crystal phase transformation in a newly synthesized glassy system (i.e., glassy SeTeSnZn alloys) consisting of chalcogenides Se and Te as major elements, Sn as a third element of the parent alloy and Zn as a chemical modifier. The role of increasing the Zn concentration at the cost of Se has been understood by correlating the kinematics of structural relaxation during the glass transition phenomenon and devitrification during the crystallization phenomenon in the chalcogenide glasses (ChGs) of the quaternary STSZ [i.e., Se78-x Zn x Te20Sn2 (0 ≤ x ≤ 6)] system and their different physicochemical properties. A noticeable rise in the crystallization rate is observed after the addition of Zn in the parent SeTeSn glass. With the rise in the zinc content, the values of average heat of atomization and overall mean bond energy are found to be decreased with the decrease in cohesive energy of samples. An inverse correlation is observed between the thermal stability parameter and the enthalpy released during the glass/crystalline phase transformation.
Collapse
Affiliation(s)
- Vishnu Saraswat
- Physics Department, Banaras Hindu University Varanasi-221005 India
| | - Shiv Kumar Pal
- Physics Department, Banaras Hindu University Varanasi-221005 India
| | - N. Mehta
- Physics Department, Banaras Hindu UniversityVaranasi-221005India
| | - Arun Kumar
- Physics Department, IIT RoorkeeRoorkee-247667India
| | - M. M. A. Imran
- Physics Department, Al-Balqa Applied UniversityAl-Salt-19117Jordan
| |
Collapse
|
5
|
Hordeaux J, Ramezani A, Tuske S, Mehta N, Song C, Lynch A, Lupino K, Chichester JA, Buza EL, Dyer C, Yu H, Bell P, Weimer JM, Do H, Wilson JM. Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase. Front Immunol 2023; 14:1094279. [PMID: 37033976 PMCID: PMC10073725 DOI: 10.3389/fimmu.2023.1094279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Accepted: 01/30/2023] [Indexed: 04/11/2023] Open
Abstract
Immune responses to human non-self transgenes can present challenges in preclinical studies of adeno-associated virus (AAV) gene therapy candidates in nonhuman primates. Although anti-transgene immune responses are usually mild and non-adverse, they can confound pharmacological readouts and complicate translation of results between species. We developed a gene therapy candidate for Pompe disease consisting of AAVhu68, a clade F AAV closely related to AAV9, that expresses an engineered human acid-alpha glucosidase (hGAA) tagged with an insulin-like growth factor 2 variant (vIGF2) peptide for enhanced cell uptake. Rhesus macaques were administered an intravenous dose of 1x1013 genome copies (GC)/kg, 5x1013 GC/kg, or 1 x 1014 GC/kg of AAVhu68.vIGF2.hGAA. Some unusually severe adaptive immune responses to hGAA presented, albeit with a high degree of variability between animals. Anti-hGAA responses ranged from absent to severe cytotoxic T-cell-mediated myocarditis with elevated troponin I levels. Cardiac toxicity was not dose dependent and affected five out of eleven animals. Upon further investigation, we identified an association between toxicity and a major histocompatibility complex class I haplotype (Mamu-A002.01) in three of these animals. An immunodominant peptide located in the C-terminal region of hGAA was subsequently identified via enzyme-linked immunospot epitope mapping. Another notable observation in this preclinical safety study cohort pertained to the achievement of robust and safe gene transfer upon intravenous administration of 5x1013 GC/kg in one animal with a low pre-existing neutralizing anti-capsid antibodies titer (1:20). Collectively, these findings may have significant implications for gene therapy inclusion criteria.
Collapse
Affiliation(s)
- Juliette Hordeaux
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Ali Ramezani
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Steve Tuske
- Amicus Therapeutics, Inc., Philadelphia, PA, United States
| | - Nickita Mehta
- Amicus Therapeutics, Inc., Philadelphia, PA, United States
| | - Chunjuan Song
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Anna Lynch
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Katherine Lupino
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Jessica A. Chichester
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Elizabeth L. Buza
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Cecilia Dyer
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Hongwei Yu
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Peter Bell
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Jill M. Weimer
- Amicus Therapeutics, Inc., Philadelphia, PA, United States
| | - Hung Do
- Amicus Therapeutics, Inc., Philadelphia, PA, United States
| | - James M. Wilson
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- *Correspondence: James M. Wilson,
| |
Collapse
|
6
|
Bartsch YC, Cizmeci D, Kang J, Zohar T, Periasamy S, Mehta N, Tolboom J, Van der Fits L, Sadoff J, Comeaux C, Callendret B, Bukreyev A, Lauffenburger DA, Bastian AR, Alter G. Antibody effector functions are associated with protection from respiratory syncytial virus. Cell 2022; 185:4873-4886.e10. [PMID: 36513064 DOI: 10.1016/j.cell.2022.11.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 08/29/2022] [Accepted: 11/11/2022] [Indexed: 12/15/2022]
Abstract
Respiratory syncytial virus (RSV) infection is a major cause of severe lower respiratory tract infection and death in young infants and the elderly. With no effective prophylactic treatment available, current vaccine candidates aim to elicit neutralizing antibodies. However, binding and neutralization have poorly predicted protection in the past, and accumulating data across epidemiologic cohorts and animal models collectively point to a role for additional antibody Fc-effector functions. To begin to define the humoral correlates of immunity against RSV, here we profiled an adenovirus 26 RSV-preF vaccine-induced humoral immune response in a group of healthy adults that were ultimately challenged with RSV. Protection from infection was linked to opsonophagocytic functions, driven by IgA and differentially glycosylated RSV-specific IgG profiles, marking a functional humoral immune signature of protection against RSV. Furthermore, Fc-modified monoclonal antibodies able to selectively recruit effector functions demonstrated significant antiviral control in a murine model of RSV.
Collapse
Affiliation(s)
- Yannic C Bartsch
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
| | - Deniz Cizmeci
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
| | - Jaewon Kang
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
| | - Tomer Zohar
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
| | - Sivakumar Periasamy
- Department of Pathology, Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA
| | - Nickita Mehta
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
| | - Jeroen Tolboom
- Janssen Vaccines & Prevention BV, 2333 Leiden, the Netherlands
| | | | - Jerry Sadoff
- Janssen Vaccines & Prevention BV, 2333 Leiden, the Netherlands
| | - Christy Comeaux
- Janssen Vaccines & Prevention BV, 2333 Leiden, the Netherlands
| | | | - Alexander Bukreyev
- Department of Pathology, Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, USA
| | - Douglas A Lauffenburger
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
| | | | - Galit Alter
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
| |
Collapse
|
7
|
Cooper M, Mehta N, Chen E. A Nutrition Labeling Online Course (NLOC) Evaluation: Assessing Users’ Feedback. J Acad Nutr Diet 2022. [DOI: 10.1016/j.jand.2022.06.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
8
|
Hamilton E, Melero I, Lugowska I, Arance Fernandez A, Vila Martinez L, Powderly J, Gutierrez M, Serino T, Mehta N, Shapiro I, Whalen K, Michaelson J, Jones J, Janik J, Moreno Garcia V. 780TiP A phase I dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB Antibody) alone and in combination with pembrolizumab in patients with advanced malignancies. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
9
|
Gonzalez-Cantero Á, Patel N, Hong C, Abbad-Jaime de Aragón C, Berna-Rico E, Solis J, Ballester A, Sorokin A, Teague H, Playford M, Barderas M, Fernandez-Friera L, Mehta N. 845 HDL composition, particle number and size is associated with non-calcified coronary plaque in psoriasis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Hsu L, Bui V, O'Hagan R, Sorokin A, Zhou W, Jones E, Mehta N, Chen M. 404 Fully Automated Quantification Of Epicardial And Thoracic Adipose Tissue From Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr 2022. [DOI: 10.1016/j.jcct.2022.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
11
|
Bui V, Hsu L, Sun A, Tran L, Shanbhag S, Chang L, Zhou W, Mehta N, Chen M. 401 Deepheartct: A Fully Automatic Hybrid Structure Segmentation Framework Based On Atlas, Reverse Ranking, And Convolutional Neural Network For Computed Tomography Angiography. J Cardiovasc Comput Tomogr 2022. [DOI: 10.1016/j.jcct.2022.06.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
12
|
Sharma S, Mehta N, Sauer T, Parikh K, Zhang H, Mehta B, Torrano V, Grilley B, Heslop H, Rooney C. Immunotherapy: EPSTEIN-BARR VIRUS (EBV) SPECIFIC T-CELLS WITH BROADER TARGET ANTIGEN REPERTOIRE FOR THE TREATMENT OF EBV+ MALIGNANCIES. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00315-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Pal S, Mehta N, Mikla V, Horvat A, Minkovich V, Dahshan A. Response to “Comment on ‘Insights into the physical aging in chalcogenide glasses: A case study of a first-generation As2Se3 binary glass’” [Coord. Chem. Rev. 442 (2021) 213992]. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2021.214205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Alsahaf M, Mehta N, Satouf A, Elliott S, Christian K. Increasing attendance of patient support groups. Physiotherapy 2021. [DOI: 10.1016/j.physio.2021.10.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
15
|
Zohar T, Hsiao JC, Mehta N, Das J, Devadhasan A, Karpinski W, Callahan C, Citron MP, DiStefano DJ, Touch S, Wen Z, Sachs JR, Cejas PJ, Espeseth AS, Lauffenburger DA, Bett AJ, Alter G. Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. Cell Host Microbe 2021; 30:41-52.e5. [PMID: 34879230 DOI: 10.1016/j.chom.2021.11.006] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 09/16/2021] [Accepted: 11/10/2021] [Indexed: 12/12/2022]
Abstract
Respiratory syncytial virus (RSV) infection is a major cause of respiratory illness in infants and the elderly. Although several vaccines have been developed, none have succeeded in part due to our incomplete understanding of the correlates of immune protection. While both T cells and antibodies play a role, emerging data suggest that antibody-mediated mechanisms alone may be sufficient to provide protection. Therefore, to map the humoral correlates of immunity against RSV, antibody responses across six different vaccines were profiled in a highly controlled nonhuman primate-challenge model. Viral loads were monitored in both the upper and lower respiratory tracts, and machine learning was used to determine the vaccine platform-agnostic antibody features associated with protection. Upper respiratory control was associated with virus-specific IgA levels, neutralization, and complement activity, whereas lower respiratory control was associated with Fc-mediated effector mechanisms. These findings provide critical compartment-specific insights toward the rational development of future vaccines.
Collapse
Affiliation(s)
- Tomer Zohar
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jeff C Hsiao
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Nickita Mehta
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
| | - Jishnu Das
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
| | - Anush Devadhasan
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
| | - Wiktor Karpinski
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA
| | | | | | | | | | - Zhiyun Wen
- Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | | | | | | | - Douglas A Lauffenburger
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | - Galit Alter
- Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
| |
Collapse
|
16
|
Gottlieb AB, Mehta N, Menter A, Mendelsohn AM, Rozzo S, Lebwohl M. AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Patients with psoriasis and metabolic syndrome (MetS) may have reduced absolute Psoriasis Area and Severity Index (PASI) response and long-term drug survival. Tildrakizumab is approved for the treatment of moderate to severe plaque psoriasis in the US, EU, Australia, and Japan. Efficacy and safety of tildrakizumab were previously shown to be comparable in patients with vs without MetS after 1 and 3 years of treatment.1Objectives:This post hoc analysis of pooled data from reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) assessed tildrakizumab efficacy and safety through up to 5 years of treatment in patients with psoriasis with and without MetS.Methods:reSURFACE 1 and 2 were 3-part, double-blind, randomized controlled phase 3 trials with long-term extensions evaluating tildrakizumab 100 or 200 mg monotherapy at Weeks 0, 4, and every 12 weeks thereafter in adults with moderate to severe plaque psoriasis.2 Patients who achieved ≥50% improvement from baseline PASI score (PASI 50 response) at both week 28 and at the end of the phase 3 studies could enter the long-term extension studies continuing the same dose of tildrakizumab.1 This post hoc analysis reports results from a pooled data analysis through up to 5 years of tildrakizumab exposure from patients with and without MetS by National Cholesterol Education Program-Adult Treatment Panel III criteria who continuously received the same dose of tildrakizumab throughout the base studies and entered the long-term extensions. Efficacy was assessed as change from baseline PASI score; missing data were handled using multiple imputation. Safety was assessed from exposure adjusted incidence rates of serious adverse events (SAEs) and treatment-emergent AEs of special interest.Results:Analyses included 70/265 patients with/without MetS receiving tildrakizumab 100 mg and 64/241 patients with/without MetS receiving tildrakizumab 200 mg. Median percentage change from baseline PASI score is shown in Figure 1. Among patients with/without MetS receiving tildrakizumab 100 mg, 78.6%/87.9% achieved PASI 75, 57.1%/63.8% achieved PASI 90, and 25.7%/32.5% achieved PASI 100 response at week 244; the PASI 75, PASI 90, and PASI 100 response rates at week 244 in patients with/without MetS receiving tildrakizumab 200 mg were 76.6%/85.1%, 46.9%/61.4%, and 26.6%/36.5%, respectively. Safety outcomes over the 5-year extension period were consistent with the known safety profile of tildrakizumab. Rates of SAEs were <8.5 per 100 patient-years among all patients, and there were no new safety signals in patients with vs without MetS (Table 1).Table 1.SAEs and TEAEs of special interest by MetS status through up to 5 years of tildrakizumab exposureTIL 100 mgTIL 200 mgWithout MetSWithMetSWithout MetSWithMetSn = 265n = 70n = 241n = 64n (EAIR per 100 PY)1149.1 PY304.1 PY1057.1 PY287.6 PYSAEs53 (4.61)22 (7.23)52 (4.92)24 (8.35)TEAEs of special interest24 (2.09)6 (1.97)27 (2.55)15 (5.22)Infections and infestations10 (0.87)2 (0.66)13 (1.23)6 (2.09)Malignanciesa5 (0.44)1 (0.33)4 (0.38)3 (1.04)Nonmelanoma skin cancer3 (0.26)1 (0.33)6 (0.57)1 (0.35)Confirmed extended MACE3 (0.26)1 (0.33)3 (0.28)3 (1.04)Drug hypersensitivity2 (0.17)1 (0.33)1 (0.09)2 (0.70)Melanoma skin cancer2 (0.17)000Injection site reactionsb1 (0.09)000Incidence rates reported as events per 100 PY.aExcluding nonmelanoma and melanoma skin cancer.bNot considered of special interest in the extension study.AE, adverse event; EAIR, exposure adjusted incidence rate; MACE, major adverse cardiovascular events; MetS, metabolic syndrome; PY, patient-years; SAE, serious AE; TEAE, treatment-emergent AE; TIL, tildrakizumab.Conclusion:The efficacy and safety of tildrakizumab were maintained in patients with and without MetS following 5 years of treatment.References:[1]Lebwohl, M et al. JAAD. 2020;S0190-9622(20)32637-2.[2]Reich K, et al. Lancet. 2017;390:276–88.Disclosure of Interests:Alice B Gottlieb Shareholder of: Xbiotech (only stock options, which she has not used)., Consultant of: Anaptyps Bio, Avotres Therapeutics; Beiersdorf; Boehringer Ingelheim; Bristol-Myers Squibb Co.; Eli Lilly; Janssen; LEO Pharma; Novartis; Sun Pharmaceutical Industries, Inc.; UCB; and Xbiotech, Grant/research support from: Boehringer Ingelheim; Janssen; Novartis; Sun Pharmaceutical Industries, Inc.; UCB; and Xbiotech., Nehal Mehta Grant/research support from: Grants to the NIH from AbbVie, Celgene, Janssen, and Novartis., Employee of: Full-time employee of the US government., Alan Menter Speakers bureau: AbbVie, Abbott Labs, Amgen, Anacor, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen Biotech, LEO Pharma, Merck & Co., Novartis, Sienna, and UCB., Consultant of: AbbVie, Abbott Labs, Amgen, Anacor, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen Biotech, LEO Pharma, Merck & Co., Novartis, Sienna, and UCB., Grant/research support from: AbbVie, Abbott Labs, Amgen, Anacor, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen Biotech, LEO Pharma, Merck & Co., Novartis, Sienna, and UCB., Alan M Mendelsohn Shareholder of: Has individual shares in Johnson and Johnson, and as part of retirement account/mutual funds, Employee of: Sun Pharmaceutical Industries, Inc., Stephen Rozzo Employee of: Sun Pharmaceutical Industries, Inc., Mark Lebwohl Consultant of: Aditum Bio; Allergan; Almirall; Arcutis; Avotres Therapeutics; BirchBioMed, Inc.; BMD Skincare; Boehringer Ingelheim; Bristol-Myers Squibb; Cara Therapeutics; Castle Biosciences; Corrona; Dermavant Sciences; Evelo; Facilitate International Dermatologic Education; Foundation for Research and Education in Dermatology; Inozyme Pharma; Kyowa Kirin; LEO Pharma; Meiji Seika Pharma; Menlo; Mitsubishi; Neuroderm; Pfizer; Promius/Dr. Reddy’s Laboratories; Serono; Theravance; and Verrica., Grant/research support from: AbbVie; Amgen; Arcutis; Boehringer Ingelheim; Dermavant; Eli Lilly; Incyte; Janssen Research & Development, LLC; LEO Pharma; Ortho Dermatologics; Pfizer; and UCB.
Collapse
|
17
|
Ogdie A, Gustafson A, Lieberman A, Mason J, Armstrong A, Mehta N, Beidas R, Gelfand J. POS1063 RHEUMATOLOGIST AND PATIENT PERSPECTIVES ON IMPLEMENTING CARDIOVASCULAR RISK PREVENTION IN THE MANAGEMENT OF PSORIASIS: A QUALITATIVE STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.902] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Psoriatic arthritis (PsA) is an immune-mediated musculoskeletal disease associated with excess risk for cardiovascular disease (CVD). New US-based guidelines recognize psoriasis as a CVD risk enhancer; however, patients with PsA often do not have CVD risk factors identified nor managed.Objectives:This study examines strategies to improve CVD prevention care from the perspective of rheumatologists and patients with PsA.Methods:Semi-structured qualitative interviews were conducted using an interview guide based on the Consolidated Framework for Implementation Research to examine the perspectives of rheumatologists (N = 8) and patients with psoriatic arthritis managed by rheumatologists (N = 8) on barriers/facilitators to CVD prevention. Interviews were transcribed and coded using an integrated approach designed to enhance reliability and validity facilitated by NVivo software.Results:Most rheumatologists confirmed that they were not regularly engaging in CVD prevention care with psoriatic arthritis patients. Providers reported sometimes counseling and screening for CVD risk, but they were not regularly prescribing statins and not as willing to do so. Reasons included a lack of familiarity or comfort with guidelines, concern about working outside of their scope of practice, confusing boundaries between other clinicians, and time constraints. Most patients confirmed that it was uncommon for their rheumatologists to engage them in CVD prevention care but expressed desire for their rheumatologists inform them of the risk, and were open to CVD prevention care from them.Conclusion:We identified several potentially modifiable barriers to CVD screening and management. These findings will inform the design of a clinical trial comparing the effectiveness of rheumatologist implementation of CVD guideline-based counseling, screening and prescribing statins when appropriate in patients with PsA.Figure 1.Barriers to CVD screening and management among patients with PsA in a rheumatology practice setting and potential strategies to address those barriers. Abbreviations: CV = cardiovascular; SOC = standard of care.Disclosure of Interests:Alexis Ogdie Consultant of: Abbvie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Grant/research support from: Pfizer to Penn, Novartis to Penn, Amgen to Forward/NDB, Alix Gustafson: None declared, Adina Lieberman: None declared, Jennifer Mason: None declared, April Armstrong: None declared, Nehal Mehta Consultant of: Amgen, Eli Lilly, and Leo Pharma receiving grants/other payments, Grant/research support from: AbbVie, Celgene, Janssen Pharmaceuticals, Inc, and Novartis receiving grants and/or research funding and as a principal investigator for the National Institute of Health receiving grants and/or research funding., Employee of: NNM is a full-time US government employee, Rinad Beidas Consultant of: Camden Coalition of Healthcare Providers in the past 3 years. She currently is a consultant for United Behavioral Health. She serves on the Optum Behavioral Health Clinical and Scientific Advisory Council. Dr. Beidas receives royalties from Oxford University Press., Joel Gelfand Shareholder of: Dr Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and he is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology., Paid instructor for: CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics, Consultant of: Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, UCB (Data Safety and Monitoring Board), Sanofi, and Pfizer Inc, Grant/research support from: research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Celgene, OrthoDermatologics, and Pfizer Inc.
Collapse
|
18
|
Kuzmin R, Grabon N, Mehta N, Burshtein A, Goldstein M, Houzet M, Glazman LI, Manucharyan VE. Inelastic Scattering of a Photon by a Quantum Phase Slip. Phys Rev Lett 2021; 126:197701. [PMID: 34047614 DOI: 10.1103/physrevlett.126.197701] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Accepted: 04/09/2021] [Indexed: 06/12/2023]
Abstract
Spontaneous decay of a single photon is a notoriously inefficient process in nature irrespective of the frequency range. We report that a quantum phase-slip fluctuation in high-impedance superconducting waveguides can split a single incident microwave photon into a large number of lower-energy photons with a near unit probability. The underlying inelastic photon-photon interaction has no analogs in nonlinear optics. Instead, the measured decay rates are explained without adjustable parameters in the framework of a new model of a quantum impurity in a Luttinger liquid. Our result connects circuit quantum electrodynamics to critical phenomena in two-dimensional boundary quantum field theories, important in the physics of strongly correlated systems. The photon lifetime data represent a rare example of verified and useful quantum many-body simulation.
Collapse
Affiliation(s)
- R Kuzmin
- Department of Physics, Joint Quantum Institute, and Quantum Materials Center, University of Maryland, College Park, Maryland 20742, USA
| | - N Grabon
- Department of Physics, Joint Quantum Institute, and Quantum Materials Center, University of Maryland, College Park, Maryland 20742, USA
| | - N Mehta
- Department of Physics, Joint Quantum Institute, and Quantum Materials Center, University of Maryland, College Park, Maryland 20742, USA
| | - A Burshtein
- Raymond and Beverly Sackler School of Physics and Astronomy, Tel Aviv University, Tel Aviv 6997801, Israel
| | - M Goldstein
- Raymond and Beverly Sackler School of Physics and Astronomy, Tel Aviv University, Tel Aviv 6997801, Israel
| | - M Houzet
- Univ. Grenoble Alpes, CEA, Grenoble INP, IRIG, PHELIQS, 38000 Grenoble, France
| | - L I Glazman
- Departments of Physics and Applied Physics, Yale University, New Haven, Connecticut 06520, USA
| | - V E Manucharyan
- Department of Physics, Joint Quantum Institute, and Quantum Materials Center, University of Maryland, College Park, Maryland 20742, USA
| |
Collapse
|
19
|
Selvan N, Mehta N, Venkateswaran S, Brignol N, Graziano M, Sheikh MO, McAnany Y, Hung F, Madrid M, Krampetz R, Siano N, Mehta A, Brudvig J, Gotschall R, Weimer JM, Do HV. Endolysosomal N-glycan processing is critical to attain the most active form of the enzyme acid alpha-glucosidase. J Biol Chem 2021; 296:100769. [PMID: 33971197 PMCID: PMC8191302 DOI: 10.1016/j.jbc.2021.100769] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Revised: 04/30/2021] [Accepted: 05/06/2021] [Indexed: 11/17/2022] Open
Abstract
Acid alpha-glucosidase (GAA) is a lysosomal glycogen-catabolizing enzyme, the deficiency of which leads to Pompe disease. Pompe disease can be treated with systemic recombinant human GAA (rhGAA) enzyme replacement therapy (ERT), but the current standard of care exhibits poor uptake in skeletal muscles, limiting its clinical efficacy. Furthermore, it is unclear how the specific cellular processing steps of GAA after delivery to lysosomes impact its efficacy. GAA undergoes both proteolytic cleavage and glycan trimming within the endolysosomal pathway, yielding an enzyme that is more efficient in hydrolyzing its natural substrate, glycogen. Here, we developed a tool kit of modified rhGAAs that allowed us to dissect the individual contributions of glycan trimming and proteolysis on maturation-associated increases in glycogen hydrolysis using in vitro and in cellulo enzyme processing, glycopeptide analysis by MS, and high-pH anion-exchange chromatography with pulsed amperometric detection for enzyme kinetics. Chemical modifications of terminal sialic acids on N-glycans blocked sialidase activity in vitro and in cellulo, thereby preventing downstream glycan trimming without affecting proteolysis. This sialidase-resistant rhGAA displayed only partial activation after endolysosomal processing, as evidenced by reduced catalytic efficiency. We also generated enzymatically deglycosylated rhGAA that was shown to be partially activated despite not undergoing proteolytic processing. Taken together, these data suggest that an optimal rhGAA ERT would require both N-glycan and proteolytic processing to attain the most efficient enzyme for glycogen hydrolysis and treatment of Pompe disease. Future studies should examine the amenability of next-generation ERTs to both types of cellular processing.
Collapse
Affiliation(s)
- Nithya Selvan
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Nickita Mehta
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Suresh Venkateswaran
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Nastry Brignol
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Matthew Graziano
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - M Osman Sheikh
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Yuliya McAnany
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Finn Hung
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Matthew Madrid
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Renee Krampetz
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Nicholas Siano
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Anuj Mehta
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Jon Brudvig
- Pediatrics & Rare Diseases Group, Sanford Research, Sioux Falls, South Dakota, USA
| | - Russell Gotschall
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Jill M Weimer
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA
| | - Hung V Do
- Discovery Science Division, Amicus Therapeutics, Inc., Philadelphia, Pennsylvania, USA.
| |
Collapse
|
20
|
Barbieri J, Beidas R, Gondo G, Williams N, Armstrong A, Ogdie A, Mehta N, Gelfand J. 251 Dermatologist preferences regarding implementation strategies to improve statin use among patients with psoriasis. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Gustafson A, Lieberman A, Mason J, Armstrong A, Ogdie A, Mehta N, Beidas R, Gelfand J. 406 Dermatologist and patient perspectives on implementing cardiovascular risk prevention in the management of psoriasis: A qualitative study. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.429] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Kanthala L, Ray S, Aurobindo Prasad Das S, Nundy S, Mehta N. Recurrent giant retroperitoneal liposarcoma: Review of literature and a rare case report. Ann Med Surg (Lond) 2021; 65:102329. [PMID: 33996060 PMCID: PMC8091881 DOI: 10.1016/j.amsu.2021.102329] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Revised: 04/11/2021] [Accepted: 04/13/2021] [Indexed: 11/26/2022] Open
Abstract
Introduction and importance Retroperitoneal liposarcomas (RPLS) are usually grow large with frequent recurrences. Complete surgical excision remains the gold standard treatment for primary and even recurrent tumours. Their prognosis depends on their histological type and grade. We report a recurrent giant de-differentiated RPLS weighing 18.55 kg which was completely excised. To the best of our knowledge, this is one of the largest liposarcoma reported in the literature. Case presentation A 40 year old female presented with a gradually progressing large abdominal lump for 1year. She had had a similar large lump twice in the past and undergone excision of the tumour elsewhere. Firm non-tender mass felt all over abdomen with edema noted over abdominal wall and bilateral lower limbs. PET CT showed large heterogeneously enhancing mass occupying almost the entire abdominopelvic cavity. 50 × 40 × 40cm tumour was completely excised and biopsy showed grade 2 dedifferentiated liposarcoma (DDLS). She is under close follow up with no recurrence at 12months. Clinical discussion DDLS have lower risk of distant metastases but have a high risk of local recurrence. The most important favourable prognostic factor in these tumours is complete resection with negative margins. Because of the ineffectiveness of current chemotherapy and the requirement of intolerably high radiation doses, surgical excision remains the most effective treatment even for the localized recurrences of RPLS. Conclusion The dedifferentiated subtype should be suspected in locally aggressive RPLS. Close follow up with early detection of recurrences and prompt excision with negative margins lowers the risk of recurrences and improves survival.
Collapse
Affiliation(s)
- Lalith Kanthala
- Department of Surgical Gastroenterology and Liver Transplantation, Sir Ganga Ram Hospital, New Delhi, 110060, India
| | - Samrat Ray
- Department of Surgical Gastroenterology and Liver Transplantation, Sir Ganga Ram Hospital, New Delhi, 110060, India
| | - Sri Aurobindo Prasad Das
- Department of Surgical Gastroenterology and Liver Transplantation, Sir Ganga Ram Hospital, New Delhi, 110060, India
| | - S Nundy
- Department of Surgical Gastroenterology and Liver Transplantation, Sir Ganga Ram Hospital, New Delhi, 110060, India
| | - N Mehta
- Department of Surgical Gastroenterology and Liver Transplantation, Sir Ganga Ram Hospital, New Delhi, 110060, India
| |
Collapse
|
23
|
Malhamé I, Danilack VA, Raker CA, Hardy EJ, Spalding H, Bouvier BA, Hurlburt H, Vrees R, Savitz DA, Mehta N. Cardiovascular severe maternal morbidity in pregnant and postpartum women: development and internal validation of risk prediction models. BJOG 2020; 128:922-932. [PMID: 32946639 DOI: 10.1111/1471-0528.16512] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/09/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVES To develop and internally validate risk prediction models identifying women at risk for cardiovascular severe maternal morbidity (CSMM). DESIGN A retrospective cohort study. SETTING An obstetric teaching hospital between 2007 and 2017. POPULATION A total of 89 681 delivery hospitalisations. METHODS We created and evaluated two models, one predicting CSMM at delivery (delivery model) and the other predicting CSMM postpartum following discharge from delivery hospitalisation (postpartum CSMM). We assessed model discrimination and calibration and used bootstrapping for internal validation. MAIN OUTCOME MEASURES Cardiovascular severe maternal morbidity comprised the following confirmed conditions: pulmonary oedema/acute heart failure, myocardial infarction, aneurysm, cardiac arrest/ventricular fibrillation, heart failure/arrest during surgery or procedure, cerebrovascular disorders, cardiogenic shock, conversion of cardiac rhythm and difficult-to-control severe hypertension. RESULTS The delivery model contained 11 variables and 3 interaction terms. The strongest predictors were gestational hypertension, chronic hypertension, multiple gestation, cardiac lesions or valvular heart disease, maternal age ≥40 years and history of poor pregnancy outcome. The postpartum model comprised eight variables. The strongest predictors were severe pre-eclampsia, non-Hispanic Black race/ethnicity, chronic hypertension, gestational hypertension, non-severe pre-eclampsia and maternal age ≥40 years at delivery. The delivery and postpartum models had an area under the receiver operating characteristic curve of 0.87 (95% CI 0.85-0.89) and 0.85 (95% CI 0.80-0.90), respectively. Both models were adequately calibrated and performed well on internal validation. CONCLUSIONS These tools may help providers to identify women at highest risk of CSMM and enable future prevention measures. TWEETABLE ABSTRACT Risk assessment tools for cardiovascular severe maternal morbidity were developed and internally validated.
Collapse
Affiliation(s)
- I Malhamé
- Department of Medicine, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.,Department of Medicine, Women and Infants Hospital, Warren Alpert School of Brown University, Providence, RI, USA
| | - V A Danilack
- Department of Obstetrics and Gynecology, Women & Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.,Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA
| | - C A Raker
- Department of Obstetrics and Gynecology, Women & Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
| | - E J Hardy
- Department of Medicine, Women and Infants Hospital, Warren Alpert School of Brown University, Providence, RI, USA.,Department of Obstetrics and Gynecology, Women & Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
| | - H Spalding
- Department of Medicine, Women and Infants Hospital, Warren Alpert School of Brown University, Providence, RI, USA
| | - B A Bouvier
- Department of Medicine, Women and Infants Hospital, Warren Alpert School of Brown University, Providence, RI, USA
| | - H Hurlburt
- Department of Medicine, Brigham and Women's Cardiovascular Associates of Care New England, Harvard Medical School, Boston, MA, USA
| | - R Vrees
- Department of Obstetrics and Gynecology, Women & Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
| | - D A Savitz
- Department of Obstetrics and Gynecology, Women & Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA.,Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA
| | - N Mehta
- Department of Medicine, Women and Infants Hospital, Warren Alpert School of Brown University, Providence, RI, USA.,Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
| |
Collapse
|
24
|
Mehta N, Le A, Chatterjee-Shin P. P507 CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: AS ASSESSMENT OF CURRENT CLINICAL PRACTICES. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Mehta N, Armagan A, Chatterjee-Shin P, Cohen J. P222 SEVERE ASTHMA: VIRTUAL PATIENT SIMULATION IMPROVES CLINICAL DECISIONS OF ALLERGISTS AND PULMONOLOGISTS. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Tran AC, Diogo GR, Paul MJ, Copland A, Hart P, Mehta N, Irvine EB, Mussá T, Drake PMW, Ivanyi J, Alter G, Reljic R. Mucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon-γ. Front Immunol 2020; 11:582833. [PMID: 33193394 PMCID: PMC7606302 DOI: 10.3389/fimmu.2020.582833] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Accepted: 09/29/2020] [Indexed: 12/31/2022] Open
Abstract
New evidence has been emerging that antibodies can be protective in various experimental models of tuberculosis. Here, we report on protection against multidrug-resistant Mycobacterium tuberculosis (MDR-TB) infection using a combination of the human monoclonal IgA 2E9 antibody against the alpha-crystallin (Acr, HspX) antigen and mouse interferon-gamma in mice transgenic for the human IgA receptor, CD89. The effect of the combined mucosal IgA and IFN-γ; treatment was strongest (50-fold reduction) when therapy was applied at the time of infection, but a statistically significant reduction of lung bacterial load was observed even when the therapy was initiated once the infection had already been established. The protection involving enhanced phagocytosis and then neutrophil mediated killing of infected cells was IgA isotype mediated, because treatment with an IgG version of 2E9 antibody was not effective in human IgG receptor CD64 transgenic mice. The Acr antigen specificity of IgA antibodies for protection in humans has been indicated by their elevated serum levels in latent tuberculosis unlike the lack of IgA antibodies against the virulence-associated MPT64 antigen. Our results represent the first evidence for potential translation of mucosal immunotherapy for the management of MDR-TB.
Collapse
Affiliation(s)
- Andy C Tran
- Institute for Infection and Immunity, St. George's University, London, United Kingdom
| | - Gil R Diogo
- Institute for Infection and Immunity, St. George's University, London, United Kingdom
| | - Matthew J Paul
- Institute for Infection and Immunity, St. George's University, London, United Kingdom
| | - Alastair Copland
- Institute for Infection and Immunity, St. George's University, London, United Kingdom
| | - Peter Hart
- Institute for Infection and Immunity, St. George's University, London, United Kingdom
| | - Nickita Mehta
- Ragon Institute, Harvard, Cambridge, MA, United States
| | | | - Tufária Mussá
- Department of Microbiology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.,Departamento de Plataformas Tecnológicas em Saúde, Instituto Nacional de Saúde, Maputo, Mozambique
| | - Pascal M W Drake
- Institute for Infection and Immunity, St. George's University, London, United Kingdom
| | - Juraj Ivanyi
- Departamento de Plataformas Tecnológicas em Saúde, Instituto Nacional de Saúde, Maputo, Mozambique.,Guy's Campus of King's College London, London, United Kingdom
| | - Galit Alter
- Ragon Institute, Harvard, Cambridge, MA, United States
| | - Rajko Reljic
- Institute for Infection and Immunity, St. George's University, London, United Kingdom
| |
Collapse
|
27
|
Gupta A, Aggarwal V, Mehta N, Abraham D, Singh A. Diabetes mellitus and the healing of periapical lesions in root filled teeth: a systematic review and meta‐analysis. Int Endod J 2020; 53:1472-1484. [DOI: 10.1111/iej.13366] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Accepted: 07/08/2020] [Indexed: 12/17/2022]
Affiliation(s)
- A. Gupta
- Department of Conservative Dentistry and Endodontics Manav Rachna University FaridabadIndia
| | - V. Aggarwal
- Department of Conservative Dentistry and Endodontics, Faculty of Dentistry Jamia Milia Islamia New Delhi India
| | - N. Mehta
- Department of Conservative Dentistry and Endodontics Manav Rachna University FaridabadIndia
| | - D. Abraham
- Department of Conservative Dentistry and Endodontics Manav Rachna University FaridabadIndia
| | - A. Singh
- Department of Conservative Dentistry and Endodontics Manav Rachna University FaridabadIndia
| |
Collapse
|
28
|
Abbas Y, Abdelkader M, Adams M, Addison A, Advani R, Ahmed T, Alexander V, Alexander V, Alli B, Alvi S, Amiraraghi N, Ashman A, Balakumar R, Bewick J, Bhasker D, Bola S, Bowles P, Campbell N, Can Guru Naidu N, Caton N, Chapman J, Chawdhary G, Cherko M, Coates M, Conroy K, Coyle P, Cozar O, Cresswell M, Dalton L, Danino J, Daultrey C, Davies K, Carrie S, Dick D, Dimitriadis PA, Doddi N, Dowling M, Easto R, Edmiston R, Ellul D, Erskine S, Evans A, Farboud A, Forde C, Fussey J, Gaunt A, Gilchrist J, Gohil R, Gosnell E, Grech Marguerat D, Green R, Grounds R, Hall A, Hardman J, Harris A, Harrison L, Hone R, Hoskison E, Howard J, Ioannidis D, Iqbal I, Janjua N, Jolly K, Kamal S, Kanzara T, Keates N, Kelly A, Khan H, Korampalli T, Kuet M, Kul‐loo P, Lakhani R, Lambert A, Lancer H, Leonard C, Lloyd G, Lowe E, Mair J, Maughan E, Gao C, Mayberry T, McCadden L, McClenaghan F, McKenzie G, Mcleod R, Meghji S, Mian M, Millington A, Mirza O, Mistry S, Molena E, Morris J, Myuran T, Navaratnam A, Noon E, Okonkwo O, Oremule B, Pabla L, Papesch E, Puranik V, Roplekar R, Ross E, Rudd J, Schechter E, Senior A, Sethi N, Sharma S, Sharma R, Shelton F, Sherazi Z, Tahir A, Tikka T, Tkachuk Hlinicanova O, To K, Tse A, Toll E, Ubayasiri K, Unadkat S, Upile N, Vijendren A, Walijee H, Wilkie M, Williams R, Williams M, Wilson G, Wong W, Wong G, Xie C, Yao A, Zhang H, Ellis M, Mehta N, Milinis K, Tikka T, Slovick A, Swords C, Hutson K, Smith ME, Hopkins C, Ng Kee Kwong F. Nasal Packs for Epistaxis: Predictors of Success. Clin Otolaryngol 2020; 45:659-666. [DOI: 10.1111/coa.13555] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Revised: 03/08/2020] [Accepted: 04/13/2020] [Indexed: 11/30/2022]
|
29
|
Mehta N, Fagerlie S, Maeglin J. THU0582 EFFECTIVE MANAGEMENT OF REFRACTORY GOUT: EFFECT OF ONLINE CONTINUING EDUCATION ON RHEUMATOLOGISTS’ KNOWLEDGE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Gout is a chronic condition with a considerable effect on patient health and quality of life. Despite the availability of multiple pharmacologic treatments and evidence-based management guidelines, treatment targets are often not achieved in patients with gout. Identification and optimal management of patients with severe or refractory gout is specially challenging.Objectives:The objective of this study was to determine if an online, continuing education activity could improve knowledge of rheumatologists regarding strategies to ensure effective and safe use of urate-lowering therapies in the management of patients with refractory gout.Methods:Educational design included an online, 30-minute, video-based discussion among two faculty experts with synchronized slides. Educational effectiveness was assessed with a repeated-pairs pre-/post-assessment study design using 3 knowledge questions and 1 confidence question, in which each individual served as his/her own control. A chi-squared test assessed differences from pre- to post-assessment. P values <.05 are statistically significant. Cramer’s V was used to calculate the effect size (<0.06 modest effect; 0.06-0.15 noticeable effect; 0.16-0.26 considerable effect; >0.26 extensive effect). The activity launched May 1, 2019, with data collected through December 30, 2019.Results:The analysis set consisted of responses from rheumatologists (n=300) who answered all assessment questions during the study period. Analysis of pre- vs post-intervention responses demonstrated a significant improvement in overall knowledge of rheumatologists with considerable educational impact (V = .201, P<.001). Average correct responses increased from 54% pre to 74% post education. Specific areas of improvement in knowledge include:•Optimal strategies for reducing the risk for immunogenicity associated with the use of pegloticase in patients with refractory gout (40% pre, 73% post; P<.001; V = .326)•Serum uric acid targets to optimize management of the patient with severe or refractory gout (45% pre, 57% post; P<.05; V = .120)•Selection of pegloticase for rapid decreases in tophi and serum uric acid in patients with refractory gout (77% pre, 91% post; P<.001; V = .187)Post-education, 32% of rheumatologists were more confident in their ability to manage patients with refractory gout.Conclusion:This study demonstrated the success of online, 30-minute, video-based discussion among two faculty experts with synchronized slides on improving the knowledge of rheumatologists regarding appropriate management of patients with refractory gout.Disclosure of Interests:None declared
Collapse
|
30
|
Maripuri S, Sadi H, Nevius A, Terenzi G, Mehta N, Dragan IF. Using Evidence-Based Dentistry in the Clinical Management of Methadone Maintenance Therapy Patients. J Evid Based Dent Pract 2020; 20:101399. [PMID: 32381408 DOI: 10.1016/j.jebdp.2020.101399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 11/23/2019] [Accepted: 01/17/2020] [Indexed: 10/25/2022]
Abstract
AIMS AND OBJECTIVES There is an increased interest to incorporate interprofessional educational models in the academic dental institutions to serve both student education and patient care. The aim of this report is to integrate evidence-based dentistry (EBD) with an interprofessional approach to treat methadone maintenance therapy (MMT) patients. Current example illustrates the case of a 26-year-old man receiving MMT who presented at Tufts University School of Dental Medicine with the chief complaint of "I want to fix my teeth." He presented with a collapsed vertical dimension of occlusion, extensive partial edentulism on both arches with bone loss, and a past history of drug abuse since the age of 16 years. MATERIALS AND METHODS The 5-step (ask, acquire, appraise, apply, assess) framework for the EBD process was used. First, the PICO (population, intervention, comparison, and outcome) question was asked, and then the literature was acquired and appraised. An expert librarian assisted in finding articles on the effects of methadone on the oral cavity and consequences that will affect dental treatment. The search was conducted on PubMed, using the following keywords: oral health, dentistry, dental health, and methadone. The search was performed from 1/1/2005 to 1/1/2018. After appraisal, the studies were applied in the clinical setting and treatment outcomes were assessed both subjectively and objectively. RESULTS The initial search identified there is sparse evidence on the topic. Only 34 articles were acquired. Based on the scientific evidence published, the interprofessional expertise of the clinical care team, and patient's perspective, 4 treatment plan options were proposed. The selected treatment plan was considered the best option considering an EBD person-centered approach. Progress of treatment, outcomes, and lessons learned were assessed. CONCLUSIONS This study demonstrates that incorporating EBD concepts and an interprofessional approach, MMT patients can be successfully treated. Future studies on this topic are recommended, specially considering the growth of the opioid epidemic in the past years and the need to treat the MMT patients and educate students.
Collapse
Affiliation(s)
- S Maripuri
- DMD Class of 2019, Tufts University School of Dental Medicine, Boston, MA, USA
| | - H Sadi
- Department of Public Health and Community Service, Tufts University School of Dental Medicine, Boston, MA, USA
| | - A Nevius
- Tufts University Hirsh Health Sciences Library, Boston, MA, USA
| | - G Terenzi
- Department of Public Health and Community Service, Tufts University School of Dental Medicine, Boston, MA, USA
| | - N Mehta
- Department of Public Health and Community Service, Tufts University School of Dental Medicine, Boston, MA, USA
| | - I F Dragan
- Department of Periodontology, Tufts University School of Dental Medicine, Boston, MA, USA.
| |
Collapse
|
31
|
Mehta N, Fujino T, Dela Cruz M, Holzhauser L, Rodgers D, Kalantari S, Smith B, Sarswat N, Nguyen A, Chung B, Uriel N, Raikhelkar J, Sayer G, Ota T, Song T, Jeevanandam V, Kim G, Grinstein J. Absence of Aortic Valve Opening after Hemodynamic Ramp Optimization Study Does Not Impact LVAD Morbidity of Mortality. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
32
|
Mehta N, Fujino T, Belkin M, DelaCruz M, Yu D, Holzhauser L, Rodgers D, Smith B, Kalantari S, Sarswat N, Chung B, Nguyen A, Uriel N, Raikhelkar J, Sayer G, Song T, Ota T, Jeevanandam V, Kim G, Grinstein J. Prognostication of Residual Mitral Regurgitation or Aortic Insufficiency after Invasive Hemodynamic Ramp Optimization. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
33
|
Wallace D, Cowling TE, Walker K, Suddle A, Gimson A, Rowe I, Callaghan C, Sapisochin G, Mehta N, Heaton N, van der Meulen J. Liver transplantation outcomes after transarterial chemotherapy for hepatocellular carcinoma. Br J Surg 2020; 107:1183-1191. [DOI: 10.1002/bjs.11559] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 01/05/2020] [Accepted: 01/27/2020] [Indexed: 12/19/2022]
Abstract
Abstract
Background
Transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) awaiting liver transplantation is widespread, although evidence that it improves outcomes is lacking and there exist concerns about morbidity. The impact of TACE on outcomes after transplantation was evaluated in this study.
Methods
Patients with HCC who had liver transplantation in the UK were identified, and stratified according to whether they received TACE between 2006 and 2016. Cox regression methods were used to estimate hazard ratios (HRs) for death and graft failure after transplantation adjusted for donor and recipient characteristics.
Results
In total, 385 of 968 patients (39·8 per cent) received TACE. Five-year patient survival after transplantation was similar in those who had or had not received TACE: 75·2 (95 per cent c.i. 68·8 to 80·5) and 75·0 (70·5 to 78·8) per cent respectively. After adjustment for donor and recipient characteristics, there were no differences in mortality (HR 0·96, 95 per cent c.i. 0·67 to 1·38; P = 0·821) or graft failure (HR 1·01, 0·73 to 1·40; P = 0·964). The number of TACE treatments (2 or more versus 1: HR 0·97, 0·61 to 1·55; P = 0·903) or the time of death after transplantation (within or after 90 days; P = 0·291) did not alter the outcome. The incidence of hepatic artery thrombosis was low in those who had or had not received TACE (1·3 and 2·4 per cent respectively; P = 0·235).
Conclusion
TACE delivered to patients with HCC before liver transplant did not affect complications, patient death or graft failure after transplantation.
Collapse
Affiliation(s)
- D Wallace
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
- Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK
| | - T E Cowling
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
| | - K Walker
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
| | - A Suddle
- Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK
| | - A Gimson
- Liver Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | - I Rowe
- Liver Unit, St James's Hospital and University of Leeds, Leeds, UK
- Leeds Institute for Data Analytics, University of Leeds, Leeds, UK
| | - C Callaghan
- Department of Nephrology and Transplantation, Renal Unit, Guy's Hospital, London, UK
| | - G Sapisochin
- Multi-Organ Transplant, Toronto General Surgery, Toronto, Ontario, Canada
- Department of General Surgery, University of Toronto, Toronto, Ontario, Canada
| | - N Mehta
- Division of Gastroenterology, Department of Medicine, University of California, San Francisco, California, USA
| | - N Heaton
- Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK
| | - J van der Meulen
- Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK
| |
Collapse
|
34
|
Wang S, Voronin Y, Zhao P, Ishihara M, Mehta N, Porterfield M, Chen Y, Bartley C, Hu G, Han D, Wells L, Tiemeyer M, Lu S. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions. J Virol 2020; 94:e01968-19. [PMID: 31941770 PMCID: PMC7081908 DOI: 10.1128/jvi.01968-19] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Accepted: 12/19/2019] [Indexed: 02/06/2023] Open
Abstract
Envelope (Env) glycoprotein of human immunodeficiency virus type 1 (HIV-1) is an important target for the development of an HIV vaccine. Extensive glycosylation of Env is an important feature that both protects the virus from antibody responses and serves as a target for some highly potent broadly neutralizing antibodies. Therefore, analysis of glycans on recombinant Env proteins is highly significant. Here, we present glycosylation profiles of recombinant gp120 proteins from four major clades of HIV-1 (A, B, C, and AE), produced either as research-grade material in 293 and CHO cells or as two independent lots of clinical material under good manufacturing practice (GMP) conditions. Almost all potential N-linked glycosylation sites were at least partially occupied in all proteins. The occupancy rates were largely consistent among proteins produced under different conditions, although a few sites showed substantial variability even between the two GMP lots. Our data confirmed previous studies in the field, showing an abundance of oligomannose on Env protein, with 40 to 50% of glycans being Man5 to Man9 on all four proteins under all production conditions. Overall, the differences in occupancy and glycan forms among different Env subtypes produced under different conditions were less dramatic than anticipated, and antigenicity analysis with a panel of six monoclonal antibodies, including antibodies that recognize glycan forms, showed that all four gp120s maintained their antibody-binding profiles. Such findings have major implications for the final production of a clinical HIV vaccine with Env glycoprotein components.IMPORTANCE HIV-1 Env protein is a major target for the development of an HIV-1 vaccine. Env is covered with a large number of sugar-based glycan forms; about 50% of the Env molecular weight is composed of glycans. Glycan analysis of recombinant Env is important for understanding its roles in viral pathogenesis and immune responses. The current report presents the first extensive comparison of glycosylation patterns of recombinant gp120 proteins from four major clades of HIV-1 produced in two different cell lines, grown either under laboratory conditions or at 50-liter GMP scale in different lots. Information learned in this study is valuable for the further design and production of HIV-1 Env proteins as the critical components of HIV-1 vaccine formulations.
Collapse
Affiliation(s)
- Shixia Wang
- Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
- Worcester HIV Vaccine, Inc., Worcester, Massachusetts, USA
| | - Yegor Voronin
- Worcester HIV Vaccine, Inc., Worcester, Massachusetts, USA
| | - Peng Zhao
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
| | - Mayumi Ishihara
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
| | - Nickita Mehta
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
| | - Mindy Porterfield
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
| | - Yuxin Chen
- Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
| | | | - Guangnan Hu
- Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
| | - Dong Han
- Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
| | - Lance Wells
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
| | - Michael Tiemeyer
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA
| | - Shan Lu
- Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
| |
Collapse
|
35
|
Hardy E, Spelke M, Emont J, Mehta N. Peripartum clostridium difficile infection: a 10-year experience at a single obstetric hospital, 2008-2018. Am J Obstet Gynecol 2019. [DOI: 10.1016/j.ajog.2019.10.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
Susalka D, Mehta N, Dermer S. P217 PATHOPHYSIOLOGIC AND THERAPEUTIC TARGETS FOR ALLERGIC ASTHMA: ONLINE EDUCATION IMPROVES ON ALLERGISTS’ KNOWLEDGE AND COMPETENCE. Ann Allergy Asthma Immunol 2019. [DOI: 10.1016/j.anai.2019.08.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
37
|
Mehta N, Dermer S, Susalka D. P157 CHRONIC IDIOPATHIC URTICARIA MANAGEMENT: ONLINE EDUCATION HAS EXTENSIVE IMPACT ON ALLERGISTS’ CLINICAL DECISIONS. Ann Allergy Asthma Immunol 2019. [DOI: 10.1016/j.anai.2019.08.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Morgaenko K, Noshin S, Stevenson W, Mehta N. P2842Sequential application of horizontal and vertical orientation on radiofrequency ablation lesions produced by thermocool smarttouch SF catheter. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Ablation lesions represent a complex interaction between the ablation catheter configuration and tissue anatomy. An understanding of each variable can assist in determination of the optimal lesion set. One such variable is the catheter orientation. With an irrigated radiofrequency ablation catheter with 6 pores (6P) near the distal tip, lesion surface area and volumes are smaller in the horizontal catheter orientation compared to the vertical catheter orientation. This finding is explained by the 6P irrigation catheter design, where irrigation fluid is discharged from six ports around the circumference of the electrode. Introduced in 2015, the ThermoCool SmartTouch® SF catheter has a 56-pore (56P) distribution to provide high density low volume irrigation settings. Irrigation catheters create smaller lesions in horizontal orientation compared to vertical orientation, however this has not been studied for the 56P irrigated catheter.
Purpose
Evaluate the impact of catheter orientation with sequential application of 56P catheter.
Methods
Ablation lesions were created on additive-free chicken model in a saline bath heated to 37°C using the 56P catheter under standard flow rate (8cc/min) conditions. Ablation energy of 20W and 30W was delivered twice for 30 seconds with 3 minutes interval between applications. Contact force (CF) of 5, 10, 15, and 20g was applied with the following conditions: horizontal catheter orientation followed by horizontal (HH), vertical by vertical (VV), horizontal by vertical (HV), and vertical by horizontal catheter orientation (VH). Measurements were obtained by lesion dissection through the midpoint by 3 independent operators. Kruskal-Wallis test was used for comparison of lesion depth, surface area and volume.
Results
Ninety-six lesions were analyzed. No coagulum or steam pops were included in the analysis. The minimum and maximum lesion depth, surface area and volume were 1.5 & 6.0 mm, 14.1 & 117.7mm2, 47.1 & 471.0 mm3 respectively. There was no significant difference in the lesion depth, surface area or volume in HH, VV, HV or VH orientation at different CF with 20W and 30W. (Fig 1)
Figure 1
Conclusion
Unlike other irrigated catheters, catheter orientation with sequential application with different CF and power did not impact lesion depth, surface area and volume with 56P catheter. This finding could be considered useful in situations where the catheter orientation could be challenging owing to tissue anatomy to achieve adequate lesion size.
Acknowledgement/Funding
UVA Health System
Collapse
Affiliation(s)
- K Morgaenko
- University of Virginia, Cardiovascular Medicine, Charlottesville, United States of America
| | - S Noshin
- University of Virginia, Cardiovascular Medicine, Charlottesville, United States of America
| | - W Stevenson
- Vanderbilt University, Heart and Vascular Center, Nashville, United States of America
| | - N Mehta
- University of Virginia, Cardiovascular Medicine, Charlottesville, United States of America
| |
Collapse
|
39
|
LOOMBA BSN G, Sharma A, Mehta N. MON-158 EFFECTIVENESS OF EXERCISE REGIMEN ON SLEEL QUALITY IN PATIENTS WITH END STAGE RENAL DISEASE ON MAINTENANCE HEMODIALYSIS. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
40
|
Mehta N, Gava A, Zhang D, Gao B, KREPINSKY J. SUN-189 FOLLISTATIN PROTECTS AGAINST ER STRESS-INDUCED OXIDATIVE STRESS AND APOPTOSIS BOTH IN VITRO AND IN VIVO IN CKD. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
41
|
Karsten CB, Mehta N, Shin SA, Diefenbach TJ, Slein MD, Karpinski W, Irvine EB, Broge T, Suscovich TJ, Alter G. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis. J Immunol Methods 2019; 471:46-56. [PMID: 31132351 PMCID: PMC6620195 DOI: 10.1016/j.jim.2019.05.006] [Citation(s) in RCA: 106] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2019] [Revised: 04/09/2019] [Accepted: 05/22/2019] [Indexed: 12/19/2022]
Abstract
Neutrophils, the most abundant white blood cell, play a critical role in anti-pathogen immunity via phagocytic clearance, secretion of enzymes and immunomodulators, and the release of extracellular traps. Neutrophils non-specifically sense infection through an array of innate immune receptors and inflammatory sensors, but are also able to respond in a pathogen/antigen-specific manner when leveraged by antibodies via Fc-receptors. Among neutrophil functions, antibody-dependent neutrophil phagocytosis (ADNP) results in antibody-mediated opsonization, enabling neutrophils to sense and respond to infection in a pathogen-appropriate manner. Here, we describe a high-throughput flow cytometric approach to effectively visualize and quantify ADNP and its downstream consequences. The assay is easily adaptable, supporting both the use of purified neutrophils or white blood cells, the use of purified Ig or serum, and the broad utility of any target antigen. Thus, this ADNP assay represents a high-throughput platform for the in-depth characterization of neutrophil function. A high-throughput antibody-dependent neutrophil phagocytosis (ADNP) assay was developed. This flow cytometry assay is flexible and can be easily adapted to any pathogen. Analysis of sample sets by ADNP assay is fast, robust and cost-effective. Additional neutrophil functions can be profiled in secondary analyses.
Collapse
Affiliation(s)
- Christina B Karsten
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
| | - Nickita Mehta
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
| | - Sally A Shin
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
| | - Thomas J Diefenbach
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
| | - Matthew D Slein
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
| | - Wiktor Karpinski
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
| | - Edward B Irvine
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA; Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA 02115, USA
| | - Thomas Broge
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
| | - Todd J Suscovich
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA
| | - Galit Alter
- Ragon Institute of MGH, MIT and Harvard, 400 Technology Square, Cambridge, MA 02139, USA.
| |
Collapse
|
42
|
Pal SK, Chandel N, Mehta N. Synthesis and thermal characterization of novel phase change materials (PCMs) of the Se-Te-Sn-Ge (STSG) multi-component system: calorimetric studies of the glass/crystal phase transition. Dalton Trans 2019; 48:4719-4729. [PMID: 30900720 DOI: 10.1039/c8dt03729a] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
According to recent literature, germanium-containing chalcogenide glasses (ChGs) show improvement in thermal stability and glass-forming ability because of the self-organization of the glass network towards a more rigid structure. The Ge-containing ChGs play a potential role as PCMs in phase-change optical memory (PCOM) applications. This endeavor reports the synthesis of some novel PCMs with Ge as the chemical modifier to improve the kinetic parameters of glass/crystal phase transition. The compositional variation of the various kinetic parameters in the present STSG chalcogen-rich non-oxide glasses Se78-yGeyTe20Sn2 (0 ≤ y ≤ 6) has been studied by means of the state-of-the-art differential scanning calorimetric (DSC) technique in the non-isothermal mode. The thermally assisted glass transition and crystallization phenomena have been investigated by examining the variation in various kinetic parameters like the characteristic kinetic temperatures (glass transition temperature Tg, on-set crystallization temperature To and peak crystallization temperature Tc), the activation energies involved in both phenomena, the thermal stability factor S and the glass-forming ability (GFA). The thermal stability factor S and GFA increase appreciably at higher concentrations of Ge as a signature of stiffness transition followed by the self-organization of the corner-sharing and the edge-sharing arrangements of the GeSe4 phase.
Collapse
Affiliation(s)
- Shiv Kumar Pal
- Physics Department, Institute of Science, Banaras Hindu University, Varanasi-221005, India.
| | | | | |
Collapse
|
43
|
Chandler KB, Mehta N, Leon DR, Suscovich TJ, Alter G, Costello CE. Multi-isotype Glycoproteomic Characterization of Serum Antibody Heavy Chains Reveals Isotype- and Subclass-Specific N-Glycosylation Profiles. Mol Cell Proteomics 2019; 18:686-703. [PMID: 30659065 PMCID: PMC6442369 DOI: 10.1074/mcp.ra118.001185] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 01/16/2019] [Indexed: 01/16/2023] Open
Abstract
Antibodies are critical glycoproteins that bridge the innate and adaptive immune systems to provide protection against infection. The isotype/subclass of the antibody, the co-translational N-glycosylation on the CH2 domain, and the remodeling of the N-linked glycans during passage through the ER and Golgi are the known variables within the Fc domain that program antibody effector function. Through investigations of monoclonal therapeutics, it has been observed that addition or removal of specific monosaccharide residues from antibody N-glycans can influence the potency of antibodies, highlighting the importance of thoroughly characterizing antibody N-glycosylation. Although IgGs usually have a single N-glycosylation site and are well studied, other antibody isotypes, e.g. IgA and IgM, that are the first responders in certain diseases, have two to five sites/monomer of antibody, and little is known about their N-glycosylation. Here we employ a nLC-MS/MS method using stepped-energy higher energy collisional dissociation to characterize the N-glycan repertoire and site occupancy of circulating serum antibodies. We simultaneously determined the site-specific N-linked glycan repertoire for IgG1, IgG4, IgA1, IgA2, and IgM in individual healthy donors. Compared with IgG1, IgG4 displayed a higher relative abundance of G1S1F and a lower relative abundance of G1FB. IgA1 and IgA2 displayed mostly biantennary N-glycans. IgA2 variants with the either serine (S93) or proline (P93) were detected. In digests of the sera from a subset of donors, we detected an unmodified peptide containing a proline residue at position 93; this substitution would strongly disfavor N-glycosylation at N92. IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms. This multi-isotype approach is a crucial step toward developing a platform to define disease-specific N-glycan signatures for different isotypes to help tune antibodies to induce protection. Data are available via ProteomeXchange with identifier PXD010911.
Collapse
Affiliation(s)
- Kevin Brown Chandler
- From the ‡Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, Massachusetts
| | - Nickita Mehta
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts
| | - Deborah R Leon
- From the ‡Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, Massachusetts
| | - Todd J Suscovich
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts
| | - Galit Alter
- Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts
| | - Catherine E Costello
- From the ‡Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, Massachusetts;.
| |
Collapse
|
44
|
Hirankumar G, Mehta N. Effect of incorporation of different plasticizers on structural and ion transport properties of PVA-LiClO 4 based electrolytes. Heliyon 2018; 4:e00992. [PMID: 30623123 PMCID: PMC6313818 DOI: 10.1016/j.heliyon.2018.e00992] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2018] [Revised: 08/17/2018] [Accepted: 11/27/2018] [Indexed: 11/14/2022] Open
Abstract
To date high ionic conducting polymer electrolytes are of great interest because of their potential applications in various electrochemical devices such as batteries, fuel cells, solar cells and super capacitors etc., as electrolytes. Ion conduction through polymer electrolytes can occur mostly in amorphous environment exists above their glass transition temperature (Tg). In order to improve ionic conductivity, many approaches such as addition of plasticizer, blending of polymers, nano composite have been employed. This paper reviews the influence of different plasticizers/additives on the ion transport mechanism of Poly(vinyl alcohol) (PVA)-LiClO4 polymer electrolytes since poly vinyl alcohol is a semi crystalline, synthetic biodegradable polymer and lithium perchlorate is one of the most moisture resistant lithium salts. This review also reveals the relation between dynamical disorder in polymer electrolyte with ionic conductivity.
Collapse
Affiliation(s)
- G Hirankumar
- Department of Physics, Ramakrishna Mission Vivekananda College, Chennai, 600004, India
| | - N Mehta
- Physics Department, Institute of Science, Banaras Hindu University, Varanasi 221005, India
| |
Collapse
|
45
|
Hussain SA, Dey B, Bhattacharjee D, Mehta N. Unique supramolecular assembly through Langmuir - Blodgett (LB) technique. Heliyon 2018; 4:e01038. [PMID: 30582053 PMCID: PMC6298938 DOI: 10.1016/j.heliyon.2018.e01038] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2018] [Revised: 06/30/2018] [Accepted: 12/07/2018] [Indexed: 12/05/2022] Open
Abstract
The Langmuir-Blodgett (LB) technique is a way of making supra-molecular assembly in ultrathin films with a controlled layered structure and crystal parameter, which have many envisioned technological applications for optical and molecular electronic devices as well as signal processing and transformation. Probably LB technique is the best method to manipulate materials at molecular level and provides a scope to realize the molecular electronics in reality. In this review article, we have discussed about the general introduction of LB technique and recent development on LB and related system including (i) LB methodology, (ii) characterizations of LB films, (iii) LB films and molecular electronics, (iv) historical review of LB films, (v) research and applications including fundamental research and application towards devices.
Collapse
Affiliation(s)
- Syed Arshad Hussain
- Thin Film and Nanoscience Laboratory, Department of Physics, Tripura University, Suryamaninagar 799022, Tripura, India
| | - Bapi Dey
- Thin Film and Nanoscience Laboratory, Department of Physics, Tripura University, Suryamaninagar 799022, Tripura, India
| | - D. Bhattacharjee
- Thin Film and Nanoscience Laboratory, Department of Physics, Tripura University, Suryamaninagar 799022, Tripura, India
| | - N. Mehta
- Physics Department, Institute of Science, Banaras Hindu University, Varanasi 221005, India
| |
Collapse
|
46
|
Abrams L, Mehta N. DEPRESSION TRAJECTORIES IN OLDER ADULTS: DIFFERENCES BY GENDER, RACE/ETHNICITY, EDUCATION, AND COHORT. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - N Mehta
- University of Michigan Department of Health Management and Policy
| |
Collapse
|
47
|
Mehta N, Dermer S. PEANUT ALLERGEN IMMUNOTHERAPY: ONLINE EDUCATION IMPROVES KNOWLEDGE OF ALLERGIST LEARNERS. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
48
|
Sorokin A, Kotani K, Dey A, Harrington C, Lerman J, Chung J, Rodante J, Bluemke D, Chen M, Playford M, Mehta N. Psoriasis specific changes in oxidized lipoproteins and its association with non-calcified coronary plaque. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Amin A, Sinha V, Sullivan T, Mehta N, Doshi M, Kuker R, Lencioni R, Narayanan G. 3:27 PM Abstract No. 184 Using FDG PET/CT to predict response to IRE in nonresectable pancreatic cancer: a retrospective analysis of 50 patients. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
50
|
Phillips E, Kohlbrenner R, True-Yasaki A, Fidelman N, Taylor A, Lehrman E, Kohi M, Kolli K, Kerlan R, Mehta N. Abstract No. 522 Outcomes of TACE for hepatocellular carcinoma in patients with HIV infection. J Vasc Interv Radiol 2018. [DOI: 10.1016/j.jvir.2018.01.567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|